ATLANTA - Femasys Inc. (NASDAQ: NASDAQ:FEMY), a biomedical company dedicated to women's healthcare solutions, has announced the appointment of Richard Spector as Chief Commercial Officer (CCO). Mr. Spector, with a notable 25-year career in healthcare company leadership, will spearhead the commercial launch of Femasys' products, including the newly FDA-cleared FemaSeed, an infertility treatment, and FemBloc, a non-surgical permanent birth control currently in late-stage clinical development.
Mr. Spector's extensive experience encompasses roles at both public and private healthcare firms, where he has been instrumental in product launches, sales and marketing, and strategic alliance management. His previous tenure includes positions at Qlibrium, Insulet (NASDAQ:PODD) Corporation, OvaScience, Inc., NeoMatrix, Inc., Advanced Radiation Therapy, LLC, and Cytyc Surgical Products, LLC.
Kathy Lee-Sepsick, Femasys' CEO and founder, expressed confidence in Spector's ability to lead the company's commercialization strategy, particularly highlighting his track record and leadership skills. Spector himself is eager to contribute to the growth of Femasys, emphasizing the potential impact of its products on women's health.
In line with his appointment, Femasys has granted Mr. Spector an inducement stock option to purchase 100,000 shares of Femasys common stock. This incentive aligns with Nasdaq Listing Rule 5635(c)(4) and is contingent on his continued employment with the company.
Femasys' portfolio includes FDA-cleared and commercially ready diagnostic products, such as FemVue for fallopian tube assessment and FemCerv for cervical cancer diagnosis. The company's focus on accessible, in-office solutions aims to address unmet medical needs for women globally.
This strategic appointment comes at a pivotal time for Femasys as it gears up to establish a stronger presence in the women's health market. The information provided is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.